Impact of EU label changes and regulatory communication on SARS-CoV-2 adenovirus vector vaccines in context of thrombosis with thrombocytopenia syndrome (TTS): risk awareness and adherence (RiskAwareTTS)

Documents

Study protocol

Initial protocol

Protocol ROC24_COVID-19_vaccines_TTS 4

Updated protocol

080422 Protocol RiskAware TTS version 3.0 final2

First published: 22/02/2024

Study results

Study results

RiskAware TTS Summary ENCEPP_SA

Study report

Other information

Publications

Study publications

Public's perspective on COVID-19 adenovirus vector vaccines after thrombosis wi…

Impact of Regulatory Risk Communication on Thrombosis With Thrombocytopenia Syn…

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

This study has been awarded the ENCePP seal

Conflicts of interest of investigators

All COI forms-Annex5

Composition of steering group and observers

Teams in RiskAware TTS project